

AMENDMENT

Please amend the application as follows:

In the Claims

1. (Previously presented) A fusion protein comprising a first sequence and a second sequence, wherein:

- (a) the first sequence comprises an antibody or binding fragment thereof, which binds to an antigen presenting cell (APC) surface molecule, wherein the APC surface molecule is selected from the group consisting of an MHC class II molecule, CD205 (DEC205), CD204, CD14, CD206, TLRs, Langerin (CD207), DC-SIGN (CD209), CD68, CD83, CD33, CD54 and BDCA-2,3,4; and
- (b) the second sequence comprises a Notch ligand or a fragment thereof, wherein:
 - (i) the second sequence comprises a Notch ligand DSL domain and at least one EGF-like repeat, ~~wherein~~;
 - (ii) the Notch ligand is selected from the group consisting of human Delta 1 comprising the amino acid sequence of SEQ ID NO: 40, human Delta 3 comprising the amino acid sequence of SEQ ID NO: 41, human Delta 4 comprising the amino acid sequence of SEQ ID NO: 42, human Jagged 1 comprising the amino acid sequence of SEQ ID NO: 43, and Jagged 2 comprising the amino acid sequence of SEQ ID NO: 44; ~~and wherein~~ and
 - (iii) the second sequence retains Notch signaling activity.

2-17. (Cancelled)

18. (Previously presented) The fusion protein according to claim 1, wherein the first sequence is an antibody or antibody fragment which binds to an MHC class II molecule.

19-28. (Cancelled)

29. (Previously presented) A fusion protein prepared by

- (a) transforming a host cell with an expression vector comprising a polynucleotide sequence encoding the fusion protein of claim 1; and
- (b) culturing the host cell under conditions which provide for expression of the fusion protein.

30. (Withdrawn) A method of targeting a protein for Notch signalling modulation, or a polynucleotide coding therefor, to an APC comprising exposing the APC to the conjugate according to claim 1.

31. (Previously presented) A composition comprising the fusion protein of claim 1 and a pharmaceutically acceptable excipient, diluent or carrier.

32. (Withdrawn) A method of preventing or treating a disease or infection a subject in need thereof, comprising administering the conjugate according to claim 1 to the subject.

33. (Withdrawn) The method according to claim 32, wherein the disease is a T-cell mediated disease.

34-36. (Cancelled)

37. (Currently amended) A fusion protein comprising[[:]] an antibody or antigen binding fragment thereof which binds to an APC surface molecule selected from the group consisting of CD205 (DEC205), CD204, CD14, CD206, TLR, Langerin (CD207), DC-SIGN (CD209), CD32, CD68, CD83, CD33, CD54, BDCA-2, BDCA-3, BDCA-4, wherein the antibody or binding fragment thereof is fused to a Notch ligand or a fragment thereof comprising a Notch ligand DSL domain and at least one EGF-like repeat, and wherein;

- (i) the Notch ligand is selected from the group consisting of human Delta1 comprising the amino acid sequence of SEQ ID NO: 40; human Delta3 comprising the amino acid sequence of SEQ ID NO: 41; human Delta4 comprising the amino acid sequence of SEQ ID NO: 42; human Jagged1 comprising the amino acid sequence of SEQ ID NO: 43; human Jagged2 comprising the amino acid sequence of SEQ ID

NO: 44 and a human Notch ligand fragment selected from the group consisting of the amino acid sequence of SEQ ID NO: 25, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 36, SEQ ID NO: 38 and SEQ ID NO: 39; and

(ii) the Notch ligand or fragment thereof retains Notch signaling activity.